Provided by Tiger Trade Technology Pte. Ltd.

Lineage Cell Therapeutics Inc

1.09
+0.01000.93%
Post-market: 1.09-0.0006-0.06%17:19 EDT
Volume:607.28K
Turnover:657.81K
Market Cap:275.67M
PE:-5.88
High:1.11
Open:1.08
Low:1.06
Close:1.08
52wk High:2.09
52wk Low:1.00
Shares:252.91M
Float Shares:191.00M
Volume Ratio:0.60
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1855
EPS(LYR):-0.2761
ROE:-60.06%
ROA:-17.04%
PB:4.53
PE(LYR):-3.95

Loading ...

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Lineage Therap (LCTX) and BioLife Solutions (BLFS)

TIPRANKS
·
Aug 07

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Reuters
·
Aug 07

Lineage Cell Therapeutics Q2 Income from Operations USD -8.923 Million

Reuters
·
Aug 07

Press Release: Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 07

Lineage Cell Therapeutics to Report Q2 Results, Host Conference Call

Reuters
·
Jul 30

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

THOMSON REUTERS
·
Jul 30

Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jul 14

Lineage Cell Therapeutics - to Advance Cor1 into In-vivo Animal Testing with Initial Data Expected This Year

THOMSON REUTERS
·
Jul 13

Lineage Provides Update on Cor1 Cell Therapy Program for Corneal Endothelial Disease

THOMSON REUTERS
·
Jul 13

Lineage Cell Therapeutics shareholders elect seven directors at annual meeting

Reuters
·
Jun 13

H.C. Wainwright Reaffirms Their Buy Rating on Lineage Therap (LCTX)

TIPRANKS
·
May 27

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)

TIPRANKS
·
May 16

Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives

Simply Wall St.
·
May 15

Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)

TIPRANKS
·
May 13

Lineage net loss widens to $4.8 million in Q1 FY26; revenue rises to $1.7 million

Reuters
·
May 13

BRIEF-Lineage Cell Therapeutics Q1 Operating Expenses USD 9.318 Million

Reuters
·
May 13

Lineage Cell Therapeutics Q1 EPS USD -0.03

THOMSON REUTERS
·
May 13

Press Release: Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)

TIPRANKS
·
May 06

Lineage Cell Therapeutics to report Q1 results, host conference call May 12

Reuters
·
May 05